Expanded FDA indications and Medicare coverage of semaglutide for cardiovascular risk prevention were associated with increased Wegovy utilization, most notably through Medicare Part D.
Christopher Scannell, MD, PhD
Advertisement
Articles by Christopher Scannell, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Ebola Cases Top 1700 as Unpaid Health Workers Strike
2
FDA Expands Approval for VWD Prophylaxis in Children Younger Than 6
3
Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers
4
Gene Therapy Could Ease Wet AMD's Injection Burden: Carl Regillo, MD
5